RxDoctor Payments Data

Eric Hensen, DO

Otolaryngology · Augusta, MENPI 1891864666

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Novartis at 24.3% of the total. Reporting peaked in 2019 at $293 and has fallen 76.2% since, to $70 in 2025.

$454in general payments, 2019–2025

Across 11 payments — averaging $41.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$110
  • Stryker$105
  • Medtronic$78
  • ARS Pharmaceuticals Operations, Inc.$48
  • Xoran Technologies LLC$40
  • Regeneron Healthcare Solutions, Inc.$26
  • plus $46 from 3 others

What the payments were for

  • Food & beverage$454100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$454 in reported general payments places this provider in the 55th percentile of 42 otolaryngology providers in Maine.

See all otolaryngology providers in Maine

Medicare billing

Part B allowed, 2024
$186,048
Medicare patients
466
Services billed
5,925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Epinephrine33$6,043
Ipratropium Bromide107$4,780
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth15$1,523
Ofloxacin34$1,074
Montelukast Sodium123$916
Dexamethasone Sodium Phosphate20$882
Pilocarpine Hcl12$673
CefuroximeCefuroxime Axetil23$531
Prednisone150$510
Hydroxychloroquine Sulfate21$508
Azelastine Hcl11$506
Pantoprazole Sodium75$404
Mupirocin18$316
ValacyclovirValacyclovir Hcl18$294
Cephalexin32$213

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Augusta

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →